{"id":726078,"date":"2023-01-26T08:03:17","date_gmt":"2023-01-26T13:03:17","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/"},"modified":"2023-01-26T08:03:17","modified_gmt":"2023-01-26T13:03:17","slug":"soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/","title":{"rendered":"Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome"},"content":{"rendered":"
\n

REDWOOD CITY, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (\u201cSoleno\u201d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that results from the Company\u2019s previously completed Phase 3 DESTINY PWS (C601) trial of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi Syndrome (PWS) have been published in a peer-reviewed journal. The article, entitled, \u201cDiazoxide Choline Extended-Release Tablet in People with Prader-Willi Syndrome: A Double-Blind Placebo-Controlled Trial,\u201d was published in The Journal of Clinical Endocrinology and Metabolism<\/em> (JCEM<\/em>) and can be found here<\/a>.<\/p>\n

\u201cWe are pleased that the data from the C601 study of DCCR in PWS have been published in a prestigious peer-reviewed journal, JCEM<\/em>,\u201d said Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics. \u201cBased on the promising results from the trial, as well as discussions with the U.S. Food and Drug Administration, we initiated a randomized withdrawal period of the open-label Phase 3 extension study C602, which has the potential to support the submission of a New Drug Application. Trial subjects are currently being randomized at our clinical sites.\u201d<\/p>\n

\n About PWS<\/strong>
\n
The Prader-Willi Syndrome Association USA\u00a0estimates that PWS occurs in one in every 15,000 live births in the\u00a0U.S.\u00a0The hallmark symptom of this disorder is hyperphagia, a chronic feeling of insatiable hunger that severely diminishes the quality of life for PWS patients and their families. Additional characteristics of PWS include behavioral problems, cognitive disabilities, low muscle tone, short stature (when not treated with growth hormone), the accumulation of excess body fat, developmental delays, and incomplete sexual development. Hyperphagia can lead to significant morbidities (e.g., obesity, diabetes, cardiovascular disease) and mortality (e.g., stomach rupture, choking, accidental death due to food seeking behavior). In a global survey conducted by the\u00a0Foundation for Prader-Willi Research, 96.5% of respondents (parent and caregivers) rated hyperphagia and 92.9 % body composition as the most important or a very important symptom to be relieved by a new medicine. There are currently no approved therapies to treat the hyperphagia\/appetite, metabolic, cognitive function, or behavioral aspects of the disorder. Diazoxide choline has received Orphan Drug Designation for the treatment of PWS in the\u00a0U.S.\u00a0and E.U., and Fast Track Designation in the\u00a0U.S.<\/p>\n

\n About DCCR (Diazoxide Choline) Extended-Release Tablets<\/strong>
\n
DCCR is a novel, proprietary extended-release dosage form containing the crystalline salt of diazoxide and is administered once-daily. The parent molecule, diazoxide, has been used for decades in thousands of patients in a few rare diseases in neonates, infants, children and adults, but has not been approved for use in PWS. Soleno conceived of and established extensive patent protection on the therapeutic use of diazoxide and DCCR in patients with PWS. The DCCR development program is supported by data from five completed Phase 1 clinical studies in healthy volunteers and three completed Phase 2 clinical studies, one of which was in PWS patients. In the PWS Phase 3 study, DCCR showed promise in addressing hyperphagia, the hallmark symptom of PWS, as well as several other symptoms such as aggressive\/destructive behaviors, fat mass and other metabolic parameters.<\/p>\n

\n About\u00a0Soleno Therapeutics, Inc.<\/strong>
\n
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company\u2019s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life<\/a>.<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding timing of any regulatory process or ultimate approvals and determining a path forward for DCCR for the treatment of PWS. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including the risks and uncertainties associated with market conditions, as well as risks and uncertainties inherent in Soleno\u2019s business, including those described in the company’s prior press releases and in the periodic reports it files with the\u00a0SEC. The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, the company does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.<\/p>\n

\n Corporate Contact:<\/strong>
\n
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

REDWOOD CITY, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (\u201cSoleno\u201d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that results from the Company\u2019s previously completed Phase 3 DESTINY PWS (C601) trial of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi Syndrome (PWS) have been published in a peer-reviewed journal. The article, entitled, \u201cDiazoxide Choline Extended-Release Tablet in People with Prader-Willi Syndrome: A Double-Blind Placebo-Controlled Trial,\u201d was published in The Journal of Clinical Endocrinology and Metabolism (JCEM) and can be found here. \u201cWe are pleased that the data from the C601 study of DCCR in PWS have been published in a prestigious peer-reviewed journal, JCEM,\u201d said Anish … <\/p>\n

Continue reading “Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-726078","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nSoleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"REDWOOD CITY, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (\u201cSoleno\u201d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that results from the Company\u2019s previously completed Phase 3 DESTINY PWS (C601) trial of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi Syndrome (PWS) have been published in a peer-reviewed journal. The article, entitled, \u201cDiazoxide Choline Extended-Release Tablet in People with Prader-Willi Syndrome: A Double-Blind Placebo-Controlled Trial,\u201d was published in The Journal of Clinical Endocrinology and Metabolism (JCEM) and can be found here. \u201cWe are pleased that the data from the C601 study of DCCR in PWS have been published in a prestigious peer-reviewed journal, JCEM,\u201d said Anish … Continue reading "Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-26T13:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjgzOCM1Mzc1MzE1IzUwMDA3Mjk5OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome\",\"datePublished\":\"2023-01-26T13:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\\\/\"},\"wordCount\":825,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNjgzOCM1Mzc1MzE1IzUwMDA3Mjk5OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\\\/\",\"name\":\"Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNjgzOCM1Mzc1MzE1IzUwMDA3Mjk5OQ==\",\"datePublished\":\"2023-01-26T13:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNjgzOCM1Mzc1MzE1IzUwMDA3Mjk5OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODczNjgzOCM1Mzc1MzE1IzUwMDA3Mjk5OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/","og_locale":"en_US","og_type":"article","og_title":"Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome - Market Newsdesk","og_description":"REDWOOD CITY, Calif., Jan. 26, 2023 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (\u201cSoleno\u201d) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that results from the Company\u2019s previously completed Phase 3 DESTINY PWS (C601) trial of DCCR (Diazoxide Choline) Extended-Release tablets for the treatment of Prader-Willi Syndrome (PWS) have been published in a peer-reviewed journal. The article, entitled, \u201cDiazoxide Choline Extended-Release Tablet in People with Prader-Willi Syndrome: A Double-Blind Placebo-Controlled Trial,\u201d was published in The Journal of Clinical Endocrinology and Metabolism (JCEM) and can be found here. \u201cWe are pleased that the data from the C601 study of DCCR in PWS have been published in a prestigious peer-reviewed journal, JCEM,\u201d said Anish … Continue reading \"Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/","og_site_name":"Market Newsdesk","article_published_time":"2023-01-26T13:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjgzOCM1Mzc1MzE1IzUwMDA3Mjk5OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome","datePublished":"2023-01-26T13:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/"},"wordCount":825,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjgzOCM1Mzc1MzE1IzUwMDA3Mjk5OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/","name":"Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjgzOCM1Mzc1MzE1IzUwMDA3Mjk5OQ==","datePublished":"2023-01-26T13:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjgzOCM1Mzc1MzE1IzUwMDA3Mjk5OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODczNjgzOCM1Mzc1MzE1IzUwMDA3Mjk5OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/soleno-therapeutics-announces-peer-reviewed-publication-of-results-from-previously-completed-phase-3-trial-of-dccr-for-treatment-of-prader-willi-syndrome\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Soleno Therapeutics Announces Peer-Reviewed Publication of Results from Previously Completed Phase 3 Trial of DCCR for Treatment of Prader-Willi Syndrome"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726078","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=726078"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/726078\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=726078"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=726078"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=726078"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}